Background-Optimal thromboprophylaxis for patients at risk of bleeding remains uncertain. This meta-analysis assessed whether intermittent pneumatic compression (IPC) of the lower limbs was effective in reducing venous thromboembolism and whether combining pharmacological thromboprophylaxis with IPC would enhance its effectiveness. Methods and Results-Two reviewers searched MEDLINE, EMBASE, and the Cochrane controlled trial register (1966( -February 2013 for randomized, controlled trials and assessed the outcomes and quality of the trials independently. Trials comparing IPC with pharmacological thromboprophylaxis, thromboembolic deterrent stockings, no prophylaxis, and a combination of IPC and pharmacological thromboprophylaxis were considered. Trials that used IPC <24 hours or compared different types of IPC were excluded. A total of 16 164 hospitalized patients from 70 trials met the inclusion criteria and were subjected to meta-analysis. IPC was more effective than no IPC prophylaxis in reducing deep vein thrombosis (7.3% versus 16.7%; absolute risk reduction, 9.4%; 95% confidence interval [CI], 7.9-10.9; relative risk, 0.43; 95% CI, 0.36-0.52; P<0.01; I 2 =34%) and pulmonary embolism (1.2% versus 2.8%; absolute risk reduction, 1.6%; 95% CI, 0.9-2.3; relative risk, 0.48; 95% CI, 0.33-0.69; P<0.01; I 2 =0%). IPC was also more effective than thromboembolic deterrent stockings in reducing deep vein thrombosis and appeared to be as effective as pharmacological thromboprophylaxis but with a reduced risk of bleeding (relative risk, 0.41; 95% CI, 0.25-0.65; P<0.01; I 2 =0%). Adding pharmacological thromboprophylaxis to IPC further reduced the risk of deep vein thrombosis (relative risk, 0.54; 95% CI, 0.32-0.91; P=0.02; I 2 =0%) compared with IPC alone. Conclusions-IPC was effective in reducing venous thromboembolism, and combining pharmacological thromboprophylaxis with IPC was more effective than using IPC alone. (Circulation. 2013;128:1003-1020.)
V enous thromboembolism is an important preventable cause of morbidity and mortality in hospitalized patients. 1 The latest data show that venous thromboembolism affects 900 000 individuals in the United States each year, increasing the overall healthcare cost substantially. 2 Evidence suggests that thromboprophylaxis is of pivotal importance in reducing the mortality and morbidity of venous thromboembolism. Although underuse of thromboprophylaxis in many situations has improved with education and automated electronic alert systems, recent studies have shown that many hospitalized patients at risk of venous thromboembolism remained not treated with thromboprophylaxis in a timely fashion. 3, 4 Because bleeding from antithrombotic agents is a strong predictor of mortality, many clinicians perceive that the risk of bleeding from pharmacological thromboprophylaxis is more important than the risk of venous thromboembolism, and this contributes to the underuse of early thromboprophylaxis. 5, 6 Clinical Perspective on p 1020
Intermittent pneumatic compression (IPC) of the lower limbs, including the thigh, calf, and foot pumps, have been in use to prevent deep vein thrombosis (DVT) for many decades. According to the latest American College of Chest Physicians evidence-based clinical practice guidelines on antithrombotic therapy and the prevention of thrombosis, 7 IPC or thromboembolic deterrent stockings (TEDS) are recommended as thromboprophylaxis for patients who are at risk of bleeding, and if venous thromboembolism risk persists and risk of bleeding subsides, pharmacological thromboprophylaxis can be substituted for mechanical thromboprophylaxis for patients at low or moderate risk of venous thromboembolism and added to mechanical prophylaxis for patients at high risk of venous thromboembolism. However, these Grade 2C recommendations were based mainly on consensus among experts or weak evidence. Whether IPC is effective in reducing venous thromboembolism, in particular pulmonary embolism (PE), compared with no prophylaxis, TEDS, or pharmacological thromboprophylaxis and whether a combination of IPC and pharmacological thromboprophylaxis is more effective than IPC alone remain uncertain. 8 We hypothesized that IPC of the lower limbs is an effective form of thromboprophylaxis, comparable to pharmacological thromboprophylaxis, but that adding pharmacological thromboprophylaxis to IPC may further improve its effectiveness in reducing venous thromboembolism. In this stratified meta-analysis, we assessed the effect of IPC on risk of venous thromboembolism compared with no IPC prophylaxis, TEDS, pharmacological thromboprophylaxis, and a combination of IPC and pharmacological thromboprophylaxis.
Methods

Data Sources and Study Selection
Two reviewers searched the Cochrane controlled trial register (2012, issue 4) and the EMBASE (January 1988-February 23, 2013) and MEDLINE (1966-February 12, 2013) databases independently. During the electronic database search, the following exploded Medical Subject Heading (MeSH) terms were used: "pneumatic compression," "sequential compression," "external compression," "intermittent compression," or "pumps" with "venous thromboembolism," "deep vein thrombosis," or "pulmonary embolism." The search was limited to clinical trials, letters, editorial reviews, or randomized, controlled trials without any language restrictions. The reference lists of related editorials, reviews, and original articles identified were searched for relevant trials. Finally the Web sites of the International Network of Agencies of Health Technology Assessment in Health Care were searched to ensure that all suitable trials were included.
In this study, only randomized, controlled trials comparing the effect of IPC with no IPC prophylaxis, TEDS, pharmacological thromboprophylaxis, and a combination of IPC and pharmacological thromboprophylaxis on risk of venous thromboembolism in hospitalized patients were included. Trials using pneumatic compression during surgery only or for <24 hours after surgery, trials comparing different compression devices without a placebo group, and trials that did not report venous thromboembolism as an outcome were excluded.
Two reviewers independently examined all identified trials to confirm that they fulfilled the inclusion criteria and recorded the trial characteristics and outcomes using a predesigned data abstraction form. This abstraction form was also used to record information on the quality of the trial such as allocation concealment, randomization method, blinding of treatment, and assessment of outcome, as well as inclusion and exclusion criteria. The grading of allocation was based on the Cochrane approach as adequate, inadequate, or uncertain. When the reported methodology and results of the included trials were unclear, the corresponding authors of the trials were contacted to clarify the data. There was no disagreement between the 2 independent reviewers in the data abstracted.
Statistical Analysis
DVT and PE were the primary outcomes of this study. The other outcomes assessed included the risk of systemic or surgical wound bleeding complications and hospital mortality. During the analyses, studies were stratified into 4 strata: comparing IPC with no IPC prophylaxis, TEDS, pharmacological thromboprophylaxis, and a combination of IPC and pharmacological thromboprophylaxis. If both the IPC group and the comparative group such as unfractionated heparin received the same concomitant background thromboprophylaxis (eg, TEDS) in the trial, this would be considered a comparison of IPC with pharmacological thromboprophylaxis because any protective effect of TEDS on venous thromboembolism should have been balanced between the 2 groups.
Outcomes were reported as absolute risk reduction and relative risk (RR) with 95% confidence interval (CI) using a random-effects model; the presence of heterogeneity between trials was assessed by the χ 2 statistics; and the extent of inconsistency was assessed using I 2 statistics. 9 
Sensitivity Analyses, Publication Bias, and Meta-Regression
To assess the reasons for any heterogeneity in the results and whether the efficacy of IPC could be different in different situations, a series of sensitivity analyses were conducted. These included a restricted analysis by excluding trials that did not use blinding in the assessment of venous thromboembolism, excluding trials that reported risk of asymptomatic PE, stratifying trials that compared the IPC group against an unfractionated heparin or a low-molecular-weight-heparin/fondaparinux group, and stratifying trials on different subgroups of patients, including only elective orthopedic patients, nonsurgical patients, nonorthopedic surgical patients, or total knee versus hip arthroplasty patients.
Publication bias was assessed by a funnel plot using either DVT or PE as an end point. Meta-regression was used to assess any potential interaction between the effectiveness of IPC and the duration of IPC use.
Results
Characteristics of the Included Studies
Of the 102 trials identified from the literature and assessed in detail, 70 trials from 15 countries involving a total of Randomized controlled trials (a) comparing IPC with no IPC prophylaxis, (b) thromboembolic deterrent stockings (TEDS), (c) comparing IPC with a pharmacological thromboprophylaxis, or (d) comparing a combination of IPC and a pharmacological thromboprophylaxis against IPC alone in hospitalized patients from MEDLINE, EMBASE, and Cochrane Controlled Trials Register Databases before 12 th February 2013 (n = 102) Trials excluded (n = 32) -Using IPC < 1 day or the exact duration of use not specified (n = 15) -Comparing two different types of IPC devices (n = 7)
Comparing different duration of therapy with IPC (n = 1) -Comparing two anticoagulants with both arms treated with IPC (n=4) -Comparing two groups with variable proportions of using IPC (n=2) -Comparing placebo with a foot flexion / extension device without pneumatic compression (n=1) -Comparing one leg with IPC against another leg without IPC in all patients and used IPC only during surgery (n=1) -Comparing sequential use of IPC initially followed by enoxaparin with enoxaparin alone at the beginning (n=1) 16 164 hospitalized patients met the inclusion criteria and were subjected to meta-analysis (Figure 1) . The majority of the studies (93%) were reported in English. There were 27 trials on orthopedic surgical patients (39%); 17 trials on general surgical, including urology patients (24%); 11 trials on neurology or neurosurgical patients (16%); 8 trials on critically ill or trauma patients (12%); 4 trials on gynecological surgery patients (6%); and 3 trials on cardiology or cardiac surgical patients (4%). Thirteen trials had >2 comparative arms in the trials.* The overall quality of the trials was modest; 37 trials (53%) had adequate allocation concealment, and 31 trials (44%) used blinding in assessing the outcomes of venous thromboembolism. The detail characteristics, outcomes, quality, and funding sources of the trials are described in the Table.
Effect of IPC on Risk of DVT, PE, and Mortality Compared With No IPC Prophylaxis or TEDS
IPC was more effective than no IPC prophylaxis in reducing DVT (40 trials: 7.3% versus 16.7%; absolute risk reduction, 9.4%; 95% CI, 7.9-10.9; RR, 0.43; 95% CI, 0.36-0.52; P<0.01; I 2 =34%) and PE (26 trials: 1.2% versus 2.8%; absolute risk reduction, 1.6%; 95% CI, 0.9-2.3; RR, 0.48; 95% CI, 0.33-0.69; P<0.01; I 2 =0%; Figures 2 and 3) . Mortality, however, was not significantly different between the 2 groups (RR, 0.89; 95% CI, 0.73-1.09; P=0.27; I 2 =0%).
In 9 trials that directly compared IPC and TEDS alone, IPC was associated with a reduced risk of DVT (RR, 0.61; 95% CI, 0.39-0.93; P=0.02; I 2 =0%) but not PE (RR, 0.64; 95% CI, 0.21-1.95; P=0.43; I 2 =0%) compared with TEDS ( Figure 4 ).
Effect of IPC on Risk of DVT, PE, Bleeding Complications, and Mortality Compared With Pharmacological Thromboprophylaxis
IPC appeared to be as effective as pharmacological prophylaxis in reducing PE (RR, 1.19; 95% CI, 0.62-2.29; P=0.59; I 2 =0%) and was associated with a reduced risk of bleeding (RR, 0.41; 95% CI, 0.25-0.65; P<0.01; I 2 =0%; Figure 5 ). However, significant heterogeneity in the risk of DVT between trials existed, and when pooled, IPC appeared to be as effective as pharmacological thromboprophylaxis in reducing DVT (RR, 0.93; 95% CI, 0.69-1.26; P=0.66; I 2 =52%; Figure 6 ). Mortality was not significantly different between the 2 groups (RR, 0.92; 95% CI, 0.44-1.90; P=0.81; I 2 =0%). 
Sensitivity Analyses
Heterogeneity in the outcome of DVT remained by comparing IPC with only low-molecular-weight-heparin or unfractionated heparin alone. The risk of DVT (14 trials: RR, 1.26; 95% 
Publication Bias and Meta-Regression
With either DVT or PE used as an end point, no significant publication bias was observed when IPC was compared with pharmacological thromboprophylaxis or no IPC prophylaxis, respectively ( Figure 7A and 7B) . Most trials used IPC as a mechanical thromboprophylaxis between 3 and 10 days, and meta-regression did not show a significant association between the duration of use of IPC and its protective effect on risk of DVT (slope=−0.1, 95% CI, −0.03 to 0.02; P=0.61; Figure 8 ).
Discussion
This stratified meta-analysis showed that IPC of the lower limbs in hospitalized patients was effective in reducing venous thromboembolism compared with no IPC prophylaxis or TEDS, that its protective effect appeared to be comparable to that of pharmacological thromboprophylaxis, and that when combined with pharmacological thromboprophylaxis its protective effect on venous thromboembolism could be further enhanced. These results have clinical significance and require careful consideration.
First, our study has confirmed the results of a previous small meta-analysis of 2270 patients that IPC is effective in reducing venous thromboembolism, 80 in both surgical and nonsurgical patients. Our study supports our traditional belief in the pathogenesis of venous thromboembolism. According to the Virchow triad, 81 venous stasis resulting from immobilization of a patient is 1 of 3 key elements in the pathogenesis of venous thromboembolism. Studies have shown that IPC of the lower limbs may improve venous blood flow in the venous system and increase fibrinolytic activity. 51, 82 Thus, it is perhaps not surprising to observe that IPC is more effective than no prophylaxis or TEDS in reducing venous thromboembolism. Using IPC alone, however, may not be completely effective in preventing thromboembolism in high-risk patients, 83 especially those with multiple risk factors for venous thromboembolism, including cancer, obesity, history of thromboembolism, or prolonged immobilization after surgery or trauma. For such patients, a multimodality approach by combining IPC and pharmacological thromboprophylaxis would be most effective in reducing venous thromboembolism because the by guest on July 25, 2017 http://circ.ahajournals.org/ Downloaded from combined use of IPC and pharmacological thromboprophylaxis can tackle both venous stasis and hypercoagulability simultaneously.
Second, underuse of thromboprophylaxis remains common in many institutions. 3, 4 IPC is an attractive option of thromboprophylaxis because it is applicable to almost all hospitalized patients, including those who have active bleeding or an increased risk of bleeding. Our results showed that IPC was superior to TEDS in reducing the risk of DVT; thus, for patients who are at high risk of bleeding, IPC will be a useful bridging measure until the risk of bleeding is deemed to be acceptable for initiation of pharmacological thromboprophylaxis. Although we could not demonstrate a significant mortality difference by using IPC as a thromboprophylaxis compared with no IPC prophylaxis, a reduction in symptomatic PE is still desirable because of its effects on the morbidity of patients and cost to the healthcare system. 84, 85 Given that the cost of the disposable component of IPC is relatively low ($180), 86 the estimated cost to reduce 1 symptomatic PE is estimated to be $10 600; this is cost-effective compared with the total costs associated with the treatment of PE and its complications ($20 000). 87, 88 Therefore, our data strongly support the American College of Chest Physicians latest clinical practice guidelines on prevention of thrombosis that IPC should be used as early as possible for hospitalized patients who have contraindications to pharmacological thromboprophylaxis and that pharmacological thromboprophylaxis should be added to IPC instead of replacing it when the risk of bleeding subsides for patients who are at high risk of venous thromboembolism.
The last consideration is the limitations of the study. First, previous reviews have shown that TEDS is effective in reducing venous thromboembolism. 89 Although our results showed that IPC was more effective than TEDS in reducing DVT, outcome data on PE were limited. Therefore, whether IPC is superior to TEDS in reducing symptomatic PE remains unproven. Second, there was significant heterogeneity in the outcome on DVT between trials comparing pharmacological thromboprophylaxis with IPC, and this was not related to whether the trials used either low-molecular-weight-heparin or unfractionated heparin. Although IPC appeared to be as effective as pharmacological thromboprophylaxis in reducing PE without significant heterogeneity between the pooled trials, it is possible that some forms of pharmacological thromboprophylaxis will be more effective than IPC in reducing DVT under certain circumstances or for those who are at high risk of venous thromboembolism. Third, IPC was used during the period when the patients were at risk of DVT in the pooled trial. Thus, the negative association between the duration of IPC use and its effectiveness does not suggest that an extended period of using IPC is not indicated for patients who remain at risk of venous thromboembolism for a prolonged period of time. Finally, although most IPC devices rely on similar mechanisms to improve venous blood flow to reduce venous thromboembolism, the number of trials that directly compared different IPC devices is limited, and whether different types of IPC will have similar efficacy in reducing venous thromboembolism and tolerability by different patient groups remains uncertain. 90, 91 
Conclusions
Applying IPC to the lower limbs was effective in reducing venous thromboembolism in hospitalized patients compared with no IPC prophylaxis or TEDS, and when combined with pharmacological thromboprophylaxis, its protective effect on DVT could be further enhanced. IPC as part of a multimodality approach to prevent venous thromboembolism in hospitalized patients is strongly recommended.
